| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9392 | NVP-LCQ195 Featured | NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM. |
|
| DC8463 | NVP-TNKS656 Featured | NVP-TNKS656(TNKS-656) is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2. |
|
| DC4110 | AZD-2281 (Olaparib) Featured | Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively. |
|
| DC9253 | ON123300 Featured | ON123300 is a novel multiple kinase inhibitor. |
|
| DC11022 | OUL35 Featured | OUL35 (NSC39047) is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of 330 nM, displays remarkable selectivity towards ARTD10 over other enzymes in the human protein family. |
|
| DC11023 | OUL35 derivative 32 | OUL35 derivative 32 is a potent and selective inhibitor of mono-ADP-ribosyltransferase PARP10/ARTD10 with IC50 of230 nM, rescues HeLa cells from ARTD10-induced cell death.. |
|
| DC5885 | Oxaliplatin Featured | Oxaliplatin is a second generation potent platinum-based anti-neoplastic agent that is believed to form inter- and intrastrand DNA adducts which activate signaling pathways culminating in apoptosis. The development of Oxaliplatin was inspired from the eff |
|
| DC8717 | PAK4-IN-1（KPT9274） Featured | PAK4-IN-1 is an inhibitor of p21-activated kinases (PAKs), with IC50 of ≤100 nM in MTT assay. |
|
| DC8469 | Palbociclib Featured | Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. |
|
| DC5067 | Palbociclib (PD0332991 HCl) Featured | Palbociclib is an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, now in Phase 3 clinical development for advanced breast cancer. |
|
| DC8470 | Palbociclib isethionate Featured | Palbociclib isethionate(PD-0332991 isethionate) is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
|
| DC8149 | Pemetrexed disodium Featured | Pemetrexed disodium is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively. |
|
| DC12203 | Pentanoic acid | Pentanoic acid, a short-chain fatty acid, is a product of bacterial metabolism and are associated with allergic skin disorders. Pentanoic acid activates ROCK signaling pathway. |
|
| DC8259 | PF0477736 Featured | PF 477736 is a CHK inhitor with Ki values of 0.49 and 47 nM for Chk1 and Chk2 respectively. A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity |
|
| DC7059 | PF-03758309 Featured | PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. |
.gif)
|
| DC5111 | PHA-680632 Featured | PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3. |
|
| DC9391 | PHA-767491 (hydrochloride) | PHA-767491 (CAY10572) Hcl is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor with IC50 values of 10/34 nM. |
|
| DC8025 | CAY10572(PHA-767491) Featured | PHA-767491 (CAY10572) is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor with IC50 values of 10/34 nM. |
|
| DC4123 | PHA-793887 Featured | PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM, respectively. |
|
| DC7231 | PHA-848125(Milciclib) Featured | PHA-848125(Milciclib) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM; >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
|
| DC7235 | PIK-75 Featured | PIK-75 is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC50 of 2 nM. |
|
| DC7237 | PJ34 HCl Featured | PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2. |
|
| DC9594 | Poloxin Featured | Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain. |
|
| DC9359 | Pralatrexate Featured | Pralatrexate(Folotyn) is an antifolate, and structurally a folate analog. |
|
| DC8075 | Purvalanol A(NG 60) Featured | Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor. |
|
| DC7256 | Purvalanol B(NG-95) Featured | Purvalanol B(NG-95) is a cyclin-dependent kinase inhibitor with IC50 values of 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. |
|
| DC7664 | Quarfloxin (CX-3543) Featured | Quarfloxin (CX-3543) is a fluoroquinolone derivative with antineoplastic activity. |
|
| DC2068 | R547 | R547 is a potent and selective CDK inhibitor with Ki and IC50 of 1-3 nM and 80 nM respectively. |
|
| DC8940 | Raltitrexed Featured | Raltitrexed(ZD1694), an inhibitor of thymidylate synthase, is an antimetabolite drug used in cancer chemotherapy. |
|
| DC7768 | RGB286638 Featured | RGB-286638 is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6. |
|
